Abstract
A new and novel non-SSRI potential treatment option for major depressive disorders is Valdoxen (agomelatine) which is currently in phase III clinical studies. Valdoxen is a norepinephrine disinhibitor (NNDI) and is also an antagonist of the 5-HT(2C) receptor.
Keywords:
MDD; NNDI; Valdoxen; major depressive disorders; norepinephrine-dopamine disinhibitor.
MeSH terms
-
Acetamides* / adverse effects
-
Acetamides* / chemistry
-
Acetamides* / pharmacology
-
Acetamides* / therapeutic use
-
Animals
-
Antidepressive Agents* / adverse effects
-
Antidepressive Agents* / chemistry
-
Antidepressive Agents* / pharmacology
-
Antidepressive Agents* / therapeutic use
-
Clinical Trials, Phase III as Topic
-
Double-Blind Method
-
Drug Evaluation, Preclinical
-
Fatigue / chemically induced
-
Headache / chemically induced
-
Humans
-
Nausea / chemically induced
-
Norepinephrine / agonists*
-
Randomized Controlled Trials as Topic
-
Receptor, Melatonin, MT1 / agonists
-
Receptor, Melatonin, MT2 / agonists
-
Receptor, Serotonin, 5-HT2C / drug effects
-
Receptor, Serotonin, 5-HT2C / physiology
-
Serotonin 5-HT2 Receptor Antagonists*
Substances
-
Acetamides
-
Antidepressive Agents
-
Receptor, Melatonin, MT1
-
Receptor, Melatonin, MT2
-
Receptor, Serotonin, 5-HT2C
-
Serotonin 5-HT2 Receptor Antagonists
-
agomelatine
-
Norepinephrine